Yahoo Finance The Zacks Analyst Blog Highlights T-Mobile US, Abbott Laboratories, Advanced Micro Devices, Intuit and Cintas
For Immediate Release
Chicago, IL – April 5, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: T-Mobile US, Inc. TMUS, Abbott Laboratories ABT, Advanced Micro Devices, Inc. AMD, Intuit Inc. INTU and Cintas Corp. CTAS.
Here are highlights from Tuesday’s Analyst Blog:
Top Stock Reports for T-Mobile, Abbott Labs and AMD
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including T-Mobile, Abbott Laboratories and Advanced Micro Devices, Inc. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of T-Mobile US have outperformed the Zacks Wireless National industry over the past year (+11.2% vs. -3.4%). The company's industry-leading growth in postpaid and broadband customers is driven by a superior 5G network and focus on customers. The company has augmented its 5G footprint by introducing 5G Home Internet services in several states.
T-Mobile plans to reach 300 million people within 2023. It intends to bring more competition to home broadband, especially in underserved rural markets. T-Mobile is on track to complete the Sprint customer network decommissioning. However, T-Mobile operates in a fiercely competitive and almost saturated U.S. telecom market, which lowers its growth potential to some extent.
Several promotional activities to lure additional customers are further eroding its profitability. Importantly, the costs incurred to gain customers and enhance revenues have not rewarded its shareholders yet. Debt obligation woes also persist.
(You can read the full research report on T-Mobile US here >>>)
Abbott Laboratories shares have declined -13.4% over the past year against the Zacks Medical - Products industry’s decline of -37.8%. The company’s total sales were negatively impacted by a decline in COVID testing-related sales. Moreover, the decline in U.S. infant formula sales due to manufacturing disruptions dented the quarter’s sales further.
However, on a positive note, excluding COVID testing sales, worldwide Diagnostics sales grew over 11% led by rapid diagnostics. Within EPD, sales increased 8% organically in the fourth quarter led by double-digit growth across several countries.
Meanwhile, the Diabetes Care business continued to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre. Abbott outperformed the industry over the past year.
(You can read the full research report on Abbott Laboratories here >>>)
Shares of AMD have outperformed the Zacks Electronics - Semiconductors industry over the past six months (+42.1% vs. +38.5%). The company expects to witness continued growth in embedded and data Center segments, partially offset by a decline in the client and gaming segments for the first quarter of 2023. Sequentially, embedded segment revenues are expected to increase.
Client and Gaming segment revenues are expected to decline, largely consistent with seasonality. Data Center segment revenues are expected to decline due to elevated levels of inventory with some cloud customers.
However, AMD is benefiting from a strong product portfolio and acquisitions including Xilinx and Pensando, which has diversified its business. Robust adoption of EPYC processors by North American hyperscalers has been a tailwind.
(You can read the full research report on AMD here >>>)
Other noteworthy reports we are featuring today include Intuit Inc. and Cintas Corp.
Why Haven’t You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Abbott Laboratories (ABT) : Free Stock Analysis Report
Advanced Micro Devices, Inc. (AMD) : Free Stock Analysis Report
Cintas Corporation (CTAS) : Free Stock Analysis Report
Intuit Inc. (INTU) : Free Stock Analysis Report
T-Mobile US, Inc. (TMUS) : Free Stock Analysis Report
